Anti-α-Synuclein Peptide for Blood-Brain Barrier Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for synucleinopathies such as Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy are limited by their inability to effectively target α-synuclein aggregation and cell-to-cell propagation, and lack clinically practical delivery methods across the blood-brain barrier.
Innovation Solution
A peptide comprising an α-synuclein binding domain derived from a reversed sequence of β-synuclein, linked to a protein transduction and proteasomal targeting domain, is administered to reduce α-synuclein aggregation, cell-to-cell propagation, and neuroinflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If genetic manipulations (anti-sense oligonucleotide and siRNA) are used to knockdown α-synuclein, then protection of dopaminergic neurons is achieved, but the ability to cross the blood-brain barrier and plasma membrane is limited
Solution Approach 1:
The therapeutic agent is divided into two separate components: siRNA for gene silencing and a cell-penetrating peptide for delivery. This segmentation allows each component to be optimized for its specific function while overcoming the delivery barrier through the peptide's membrane-trans penetrating capability
Solution Approach 2:
A cell-penetrating peptide acts as an intermediary carrier that facilitates the transport of siRNA across the blood-brain barrier and plasma membrane. The peptide mediates the delivery process by binding to siRNA and enabling its passage through biological barriers that would otherwise block entry
2Productivity
If invasive intracerebral injection or viral infection is used to deliver siRNA to the brain, then delivery efficiency is improved, but clinical practicality deteriorates
Solution Approach 1:
The cell-penetrating peptide enables the siRNA to deliver itself across the blood-brain barrier without requiring invasive procedures or viral vectors. The peptide's inherent membrane-trans penetrating property allows the therapeutic complex to autonomously cross biological barriers through systemic administration
Solution Approach 2:
The invention replaces invasive mechanical delivery methods (intracerebral injection) and complex biological systems (viral vectors) with a simpler peptide-based delivery mechanism that can be administered systemically, thereby improving clinical practicality while maintaining delivery efficiency
3Ease of operation
If coupling siRNA with brain delivery vehicles (RVG-9R peptide or exosomes) is used, then blood-brain barrier crossing is partially improved, but technical challenges and restrictions remain
Solution Approach 1:
The invention extracts and utilizes only the essential membrane-trans penetrating property from complex delivery vehicles like RVG-9R peptide and exosomes. By isolating this key functional characteristic, the invention creates a simplified delivery system that achieves blood-brain barrier penetration without the technical complexities and cellular restrictions of the original vehicles
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide effectively reduces α-synuclein levels and protects against neuronal damage, ameliorating symptoms and improving motor function in animal models of Parkinson's disease.
Implementation Method 1
a peptide comprising an α-synuclein binding domain operably linked to a protein transduction domain and a proteasomal targeting domain
Implementation Method 2
proteasome-dependent, peptide-mediated knockdown of α-synuclein
Data Source
AI summary
Disclosed is a method of treating a neurodegenerative disease such as Parkinson's disease, diffuse Lewy body disease, transitional Lewy body dementia, and multiple system atrophy in a subject. The method comprises administering to the subject a therapeutically effective amount of a peptide comprising an α-synuclein binding domain operably linked to a protein transduction domain and a proteasomal targeting domain, wherein the α-synuclein binding domain is derived from a reversed sequence of β-synuclein. Other methods, as well as uses and compositions, are disclosed.